In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Other Products:

HBW Insight | Medtech Insight | Pink Sheet
Generics Bulletin | Scrip | Report Store

Register

Sign In

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Existing Subscriber? Sign in to continue reading.

New to In Vivo? Start a free trial today!

Register for our free email digests:

Existing Subscriber? Sign in to continue reading.

New to In Vivo? Start a free trial today!

Register for our free email digests:

Email
Share

Eisai promotes Pfizer's Fragmin in the US

Oct 2005

Executive Summary

Pfizer licensed Eisai Inc. exclusive rights to promote its Fragmin (dalteparin sodium) injectable anticoagulant in the US.

Deal Industry

Pharmaceuticals

Deal Status

Final

Deal Type

Alliance
- Marketing-Licensing

Already a Strategic Transactions subscriber? You have access to the full deal record through your subscription

Want to become a subscriber? Subscribers get more deal details, updates, deal financials and deal products.

Questions?

Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com

Related Companies

Advertisement

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

Eisai promotes Pfizer's Fragmin in the US

All set! This article has been sent to my@email.address.

All fields are required. For multiple recipients, separate email addresses with a semicolon.

DCD.EmailPopout.Notice